 |
|
A National Survey of Immunization Practices Following Allogeneic Bone Marrow Transplantation
Kelly J. Henning, MD;
Mary H. White, MD;
Kent A. Sepkowitz, MD;
Donald Armstrong, MD
JAMA. 1997;277(14):1148-1151.
Abstract
| |
Objectives.
—To describe the frequency and patterns of use of routine childhood and hepatitis B, pneumococcal, influenza, and meningococcal vaccines following allogeneic bone marrow transplantation (BMT).
Design, Setting, and Participants.
—Survey of all US transplantation centers participating in the National Marrow Donor Program (NMDP) during 1994.
Main Outcome Measures.
—Use, timing, and total doses of selected vaccines given to patients younger than 7 years and patients aged 7 years or older following allogeneic BMT.
Results.
—Of 66 centers associated with the NMDP, 45 (68%) responded. A total of 97% of centers performing transplants on patients younger than 7 years and 88% of centers performing transplants on patients aged 7 years or older gave either the diphtheria-tetanus vaccine or the diphtheria-tetanus-pertussis vaccine compared with 77% and 58% usage, respectively, of Haemophilus influenza type b conjugate vaccine (P=.03 and.003, respectively). Centers were more likely to administer inactivated poliovirus and measles-mumps-rubella vaccines to patients younger than 7 years than to the older age group (94% vs 73% for poliovirus, P=.02; and 94% vs 70% for measles-mumps-rubella, P=.01). About one half of centers routinely administer hepatitis B vaccine and approximately three quarters immunize with pneumococcal and influenza vaccines. Few programs, regardless of age of bone marrow recipient, use multiple vaccine ( 2) doses. The number of schedules reported for specific vaccines varied widely (3-11 schedules per vaccine).
Conclusions.
—Despite convincing evidence that patients lose protective antibodies to vaccine-preventable diseases following allogeneic BMT and accumulating data showing the safety and efficacy of many vaccines after BMT, vaccines are underutilized and schedules vary widely at US transplant centers. National guidelines for optimal doses and timing of vaccines after BMT are warranted.
Author Affiliations
for the Participating Centers
From the Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, NY (Drs Henning, White, Sepkowitz, and Armstrong). Dr Henning is now with the Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, Pa.
Footnotes
The 45 centers that participated in this study are listed at the end of this article.
Reprints: Kelly J. Henning, MD, Thomas Jefferson University, 1015 Chestnut St, Suite 610, Philadelphia, PA 19107.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
Hakki et al.
Blood 2003;102:3060-3067.
ABSTRACT
| FULL TEXT
Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols
Duchini et al.
Clin. Microbiol. Rev. 2003;16:357-364.
ABSTRACT
| FULL TEXT
Safety of early immunization against measles/mumps/rubella after bone marrow transplantation
Shaw et al.
Blood 2002;99:3486-3487.
FULL TEXT
Preventing Opportunistic Infections After Hematopoietic Stem Cell Transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond
Sullivan et al.
ASH Education Book 2001;2001:392-421.
ABSTRACT
| FULL TEXT
|
